Scarica l'app Stockscreener
27.79
1.02%
0.28
Dopo l'orario di chiusura:
26.90
-0.89
-3.20%
Uniqure N V Borsa (QURE) Ultime notizie
NASDAQ: QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
What data driven models say about uniQure N.V.’s futureMarket Volume Report & Long Hold Capital Preservation Tips - newser.com
Predicting uniQure N.V. trend using moving averages2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
uniQure NV Hits Day Low of $26.25 Amid Price Pressure - Markets Mojo
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer - GlobeNewswire
NASDAQ: QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Uniqure NV expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Volatility clustering patterns for uniQure N.V.Entry Point & Short-Term Trading Opportunity Alerts - newser.com
Can uniQure N.V. (UQ1) stock sustain revenue momentumJuly 2025 Patterns & Fast Moving Trade Plans - newser.com
UniQure’s FDA Nightmare: How A Single Therapy Sparked A $300M Meltdown! - Smartkarma
Is uniQure N.V. stock trading at a premium valuation2025 Key Lessons & Daily Technical Forecast Reports - newser.com
uniQure to Announce Third Quarter 2025 Financial Results - The Manila Times
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - MSN
uniQure (NASDAQ: QURE) to Host Earnings Call Nov. 10 at 8:30 a.m. ET, before market open - Stock Titan
The FDA is a mess, but don’t blame it for everything - statnews.com
uniQure N.V. stock outlook for YEARMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
What catalysts could drive uniQure N.V. stock higherPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Risk adjusted return profile for uniQure N.V. analyzedJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Can uniQure N.V. stock hit record highs againJuly 2025 Institutional & Fast Entry and Exit Trade Plans - newser.com
How institutional buying supports uniQure N.V. stockMarket Activity Recap & Entry Point Confirmation Signals - newser.com
Can uniQure N.V. stock hit analyst price targets2025 Biggest Moves & Verified Entry Point Detection - newser.com
Has uniQure’s Volatile 63% Drop Created a Compelling Opportunity After Pipeline News? - simplywall.st
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection - Benzinga
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of ... - Bluefield Daily Telegraph
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
uniQure (NASDAQ:QURE) Trading Down 14.7% Following Analyst Downgrade - MarketBeat
uniQure NV Hits Day Low of $22.85 Amid Price Pressure - Markets Mojo
Y Intercept Hong Kong Ltd Purchases New Stake in uniQure N.V. $QURE - MarketBeat
uniQure (QURE): Examining Valuation Following Recent Share Price Volatility - simplywall.st
Goldman Sachs Maintains uniQure N.V. (QURE) Neutral Recommendation - Nasdaq
Traders Purchase Large Volume of uniQure Call Options (NASDAQ:QURE) - MarketBeat
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential ... - Enidnews.com
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces - GlobeNewswire
QURE ALERT: UniQure Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact The Firm - ACCESS Newswire
UniQure Is Latest Gene Therapy Sponsor Surprised By US FDA Reversal - Citeline News & Insights
Chardan Capital Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price - MarketBeat
Top Small Cap Stocks To Follow TodayNovember 3rd - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - ACCESS Newswire
uniQure N.V. Securities Lawsuit Investigation - Claim Depot
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy - Benzinga
uniQure (QURE) Sees Analyst Price Target Lowered by RBC Capital - GuruFocus
uniQure (NASDAQ:QURE) Shares Gap DownHere's Why - MarketBeat
uniQure (QURE) Analyst Rating Update: Goldman Sachs Lowers Price Target | QURE Stock News - GuruFocus
uniQure (QURE) Shares Drop Over 15% Amid Market Shifts - GuruFocus
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $38 - 富途牛牛
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Business Wire
UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE) - Seeking Alpha
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $70 - 富途牛牛
Chardan Cuts Price Target on uniQure to $53 From $76, Keeps Buy Rating - MarketScreener
RBC Cuts Price Target on uniQure to $45 From $65, Keeps Outperform, Speculative Risk - MarketScreener
William Blair Downgrades uniQure N.V to Market Perform From Outperform - MarketScreener
uniQure (QURE) Downgraded by William Blair to Market Perform | Q - GuruFocus
uniQure stock price target lowered to $70 at H.C. Wainwright on FDA setback - Investing.com Nigeria
5.44%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):